Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 477Neoplasms 292Breast Neoplasms 281Colorectal Neoplasms 223Neoplasm Metastasis 188Prostatic Neoplasms 168Ovarian Neoplasms 166Lung Neoplasms 155Multiple Myeloma 153Recurrence 132Melanoma 116Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 105Endometrial Neoplasms 99Stomach Neoplasms 98Leukemia, Myeloid, Acute 97Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Triple Negative Breast Neoplasms 81Lymphoma, Non-Hodgkin 81Carcinoma, Renal Cell 80Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 76Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 64Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Colitis, Ulcerative × 90 days × Clear all
NCT02808780 2026-06-05

OPAL

Janssen Biotech, Inc.

Active not recruiting
535 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Neoplasms

NCT05156125 2026-04-30

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Oppilan Pharma Ltd

Phase 2 Terminated
213 enrolled 19 charts
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡